Finance

Lists
E4NA:FRA
Arovella Therapeutics Ltd
€0.039
0.00%
(0.00) 1D
Jul 21, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for E4NA...
Open
€0.04
High
€0.04
Low
€0.04
Mkt. cap
72.96M
Avg. vol.
334.00
Volume
0.00
52-wk high
€0.06
52-wk low
€0.04
No. of employees
14
Open
€0.04
High
€0.04
Low
€0.04
Mkt. cap
72.96M
Avg. vol.
334.00
Volume
0.00
52-wk high
€0.06
52-wk low
€0.04
No. of employees
14
News stories
From sources across the web
About Arovella Therapeutics Ltd
CEOMichael Baker
Employees14
Founded1999
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in AUD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in AUD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
415.00
415.00
1.60M
1.60M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1.97M
1.97M
1.37M
1.37M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
523.20K
523.20K
721.91K
721.91K
Operating expense
3.10M
3.10M
2.75M
2.75M
Total operating expenses
3.10M
3.10M
2.75M
2.75M
Operating income
-3.10M
-3.10M
-1.15M
-1.15M
Other non operating income
-
-
-
-
EBT including unusual items
-3.02M
-3.02M
-939.35K
-939.35K
EBT excluding unusual items
-3.02M
-3.02M
-939.35K
-939.35K
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
402.20K
402.20K
449.58K
449.58K
Net income
-3.02M
-3.02M
-939.35K
-939.35K
Net profit margin
-728,624.58%
-728,624.58%
-58.55%
-58.55%
Earnings per share
-
-
-
-
Interest and investment income
72.24K
72.24K
207.81K
207.81K
Interest expense
-
-
-
-
Net interest expenses
72.24K
72.24K
207.81K
207.81K
Depreciation and amortization charges
29.20K
29.20K
29.58K
29.58K
EBITDA
-3.07M
-3.07M
-1.12M
-1.12M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more